By VFC’s Stockhouse
Dendreon (NASDAQ:DNDN) announced earnings this week, as expected, and there were no surprises as it has been expected that the company will continue having problems meeting the high demand for Provenge until the manufacturing capacity increases, which should be the case later this year.
That said, Provenge sales increased from $20 to $24 million quarter-over-quarter, although losses also grew significantly, but again, that is mainly attributed to bringing the manufacturing plants on line.
Look for major growth in Provenge revenue towards the end of the year, and on the other side of the coin, keep an eye out for setbacks at the manufacturing plants that might delay them coming on line in the expected time frame.
Still a stellar stock story, and there’s still plenty of room for growth.
Disclosure: No position
VFC’s Stock House offers investing opinions, insight and ideas on a variety of different stocks, options or ETF’s as well as commenting on news that effects the market.
Related Articles:
Radient Pharmaceuticals (AMEX:RPC) Victim of Unwarranted Hatchet Job
Biotech Analyst Activity: PLX, HGSI, XNPT, SPPI
Epicept’s (NASDAQ:EPCT): Are Fourth Quarter Results Showing the Potential?
Protalix (AMEX:PLX) Receives CRL from FDA for Taliglucerase Alfa
Xenoport (NASDAQ:XNPT) Expecting GERD Study Data
SIGA Technologies (NASDAQ:SIGA) Spikes On Contract Possibilities
Forest Laboratories (NYSE:FRX) to Acquire Clinical Data (NASDAQ:CLDA)
Generex Biotechnology (GNBT): Earnings Alert
Delcath Sytems (NASDAQ:DCTH) Receives Refusal to File Letter from the FDA
Biotech Analyst Activity: PLX, HGSI, XNPT, SSPI
ImmunoCellular Therapeutics (OTC:IMUC): Worth Buying on the Retreat?
To discuss this article or any stock, please visit The Playground Discussion Forum!
